Journal of Clinical Oncology, Vol 14, 1903-1912, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer

SP Joel, P Ellis, K O'Byrne, D Papamichael, M Hall, R Penson, S Nicholls, C O'Donnell, A Constantinou, J Woodhull, M Nicholson, I Smith, D Talbot and M Slevin
Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London. joel@icrf.icnet.uk

PURPOSE: To investigate the feasibility of therapeutic monitoring of etoposide at different plasma concentrations of the drug, and the resulting pharmacodynamic effects of such an approach. PATIENTS AND METHODS: Forty-nine previously untreated small-cell lung cancer (SCLC) patients received single-agent etoposide every 3 weeks by continuous infusion over 5 days. Plasma etoposide concentrations were monitored 18 and 66 hours into the infusion to permit dose modification. The first cohort of 15 patients began treatment with etoposide 2 micrograms/mL, with dose escalation to 3 micrograms/mL for cycles 3 and 4 and 4 micrograms/mL for cycles 5 and 6, toxicity permitting. The second cohort of 34 patients commenced at 3 micrograms/mL, with dose escalation to 4 and 5 micrograms/mL on cycles 3 and 5, respectively. RESULTS: Mean plasma etoposide concentration during the first treatment cycle was 93.4% +/- 26.6% of the target level at 18 hours (57% of patients within +/- 20% of the target) and 98.9% +/- 14.5% of the target level at 66 hours (82% of patients within +/- 20%). Hematologic toxicity was more pronounced in those treated with 3 micrograms/mL versus 2 micrograms/mL (median nadir neutrophil count, 1.3 v 2.6 x 10(9)/L, P = .032). Tumor responses, typically documented by the third cycle, were similar in each cohort (71% in patients commenced at 2 micrograms/mL and 70% at 3 micrograms/mL). Treatment cohort was not independently predictive of survival. CONCLUSION: Therapeutic monitoring of infusional etoposide is feasible and dramatically reduces interpatient pharmacokinetic variability. Although this was a small nonrandomized trial, the observation of different hematologic toxicity at the two starting concentrations but similar antitumor activity further suggests that these effects may be associated with different plasma etoposide concentrations.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Alnaim Therapeutic drug monitoring of cancer chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 207 - 221. [Abstract] [PDF]

				L. D. Mayo, Y. R. Seo, M. W. Jackson, M. L. Smith, J. R. Guzman, C. K. Korgaonkar, and D. B. Donner Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified J. Biol. Chem., July 15, 2005; 280(28): 25953 - 25959. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, N. C. Levitt, S. Joel, T. Davis, S. Madhusudan, H. Turley, S. Wilner, A. L. Harris, and D. C. Talbot Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase II{alpha} Expression Clin. Cancer Res., October 15, 2003; 9(13): 4682 - 4688. [Abstract] [Full Text] [PDF]

				S. N. Gardner A Mechanistic, Predictive Model of Dose-Response Curves for Cell Cycle Phase-specific and -nonspecific Drugs Cancer Res., March 1, 2000; 60(5): 1417 - 1425. [Abstract] [Full Text]